ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 560

Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort

Daniel WENDLING1, Clément PRATI 2, Alain Saraux 3, Anna Moltó 4, Thao PHAM 5, Maxime Dougados 6 and Xavier GUILLOT 7, 1Rheumatology, University Teaching Hospital (CHRU), Besançon, France, 2University Teaching Hospital (CHRU), Besançon, France, 3CHU de la Cavale-Blanche Brest, Brest, France, 4Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 5CHU, Marseille, France, 6Cochin Hospital, Paris, France, 7CHU, Saint Denis de la Réunion, Reunion

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Spondylarthropathy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Dactylitis is a particular feature shared across the several phenotypical forms of spondyloarthritis (SpA), part of the classification criteria. There are only few data available about incidence of dactylitis in early stage of SpA, and factors associated with dactylitis.

Aim

To study, over 5 years in the DESIR cohort, the prevalence and incidence of dactylitis and to look at the factors associated with presence/incidence of dactylitis.

Methods: DESIR is a prospective observational cohort of patients with recent onset (less than 3 years) inflammatory back pain, beginning before 50 years, suggestive of axial SpA, All available factors in the database (clinical, biological, imaging and medico economic) were compared between patients with and without past or present dactylitis at 5 years (for categorical variables : odds-ratio +/- 95% CI and chi-square/Fisher tests, for continuous variables : unpaired t-tests / Mann-Whitney) , by uni and then multivariate analysis (logistic regression). Baseline factors associated with new cases of dactylitis occurrence were also analyzed. Significance: p less than 0.05.

Results: After 5 years, 138 cases of dactylitis were recorded in 480 patients with complete follow-up : prevalence 28.75 % [CI 95% 24.75-32.75]. At 5 years, dactylitis was significantly associated (multivariate analysis) with : Achilles enthesitis (OR : 3.3), history of psoriasis (OR: 3.9), cumulative number of ASAS criteria (OR: 7.2), modified New York criteria fulfillment (OR: 0.35), DMARD use (OR: 2.7) and elevated CRP (OR:0.9).

Incident new cases were recorded in 41 patients, with an estimated incidence of 1.7/100 patient-years. These incident cases were significantly associated with some baseline factors (multivariate analysis) : female gender (OR: 3.6), psoriasis (OR:3.4), HAQ over median (OR: 5.7), IL-31 levels over median (OR: 1.04), ASQol over median (OR: 0.84), IL-6 over median (0.83).

Conclusion: In the DESIR cohort of patients suspected for early SpA, dactylitis presence or history is recorded in 28.7 % of the cases at 5 years, with an estimated incidence of 1.7/100 p-y over 5 years. It is an early feature associated with peripheral involvement, psoriasis, more frequent use of DMARDs, but with less structural damage. Female gender and psoriasis are associated with incidence of new cases of dactylitis over 5 years in this population.


Disclosure: D. WENDLING, None; C. PRATI, None; A. Saraux, None; A. Moltó, None; T. PHAM, None; M. Dougados, AbbVie, 2, 5, 8, Amgen, 5, Biogen, 5, BMS, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, Merck, 2, 5, Merck Inc, 2, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; X. GUILLOT, None.

To cite this abstract in AMA style:

WENDLING D, PRATI C, Saraux A, Moltó A, PHAM T, Dougados M, GUILLOT X. Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/dactylitis-occurrence-in-early-spondyloarthritis-five-years-data-from-a-french-national-prospective-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dactylitis-occurrence-in-early-spondyloarthritis-five-years-data-from-a-french-national-prospective-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology